Combined pre- and post-capillary pulmonary hypertension in left heart disease

• Published in: Heart failure reviews Vol. 28; no. 1; pp. 137 - 148
• Main Authors: Riccardi, M., Pagnesi, M., Sciatti, E., Lombardi, C. M., Inciardi, R. M., Metra, M., Vizzardi, E.
• Format: Journal Article
• Language: English
• Published: New York Springer US 01-01-2023; Springer Nature B.V
• Subjects: Alveoli; Cardiology; Cardiovascular diseases; Clinical trials; Congestive heart failure; Diabetes mellitus; Echocardiography; Endothelin 1; Endothelin Receptor Antagonists - therapeutic use; Endothelins; Familial Primary Pulmonary Hypertension - complications; Familial Primary Pulmonary Hypertension - drug therapy; Female; Guanylate cyclase; Heart diseases; Heart Diseases - drug therapy; Heart Failure; Humans; Hypertension; Hypertension, Pulmonary - complications; Hypertension, Pulmonary - drug therapy; Medicine; Medicine & Public Health; Patients; Prostacyclin; Pulmonary hypertension; Risk factors; Heart failure; Pulmonary artery wedge pressure; Echocardiography; Right heart catheterization; Combined pre- and post-capillary pulmonary hypertension; Phosphodiesterase 5 inhibitors
• ISSN: 1573-7322; 1382-4147; 1573-7322
• DOI: 10.1007/s10741-022-10251-9

Patients with heart failure (HF) often have pulmonary hypertension (PH), which is mainly post-capillary; however, some of them also develop a pre-capillary component. The exact mechanisms leading to combined pre- and post-capillary PH are not yet clear, but the phenomenon seems to start from a passive transmission of increased pressure from the left heart to the lungs, and then continues with the remodeling of both the alveolar and vascular components through different pathways. More importantly, it is not yet clear which patients are predisposed to develop the disease. These patients have some characteristics similar to those with idiopathic pulmonary arterial hypertension (e.g., young age and frequent incidence in female gender), but they share cardiovascular risk factors with patients with HF (e.g., obesity and diabetes), with both reduced and preserved ejection fraction. Thanks to echocardiography parameters and newly introduced scores, more tools are available to distinguish between idiopathic pulmonary arterial hypertension and combined PH and to guide patients’ management. It may be hypothesized to treat patients in whom the pre-capillary component is predominant with specific therapies such as those for idiopathic pulmonary arterial hypertension; however, no adequately powered trials of PH-specific treatment are available in combined PH. Early evidence of clinical benefit has been proven in some trials on phosphodiesterase type 5 inhibitors, while data on prostacyclin analogues, endothelin-1 receptor antagonists, and soluble guanylate cyclase stimulators are still controversial.